ABT-RTA 408 is a small molecule Nrf-2 activator being investigated to treat Mitochondrial Myopathy and Friedreich's Ataxia. It is being developed in collaboration with Reata.

Type of Molecule

Small Molecule

Target

Nrf-2

Region

n/a

Potential Indication Product Type Phase (1, 2, 3, Submitted, Approved)
Mitochondrial Myopathy New Indication Phase 2
Friedreich’s Ataxia New Indication Phase 2